Media stories about NxStage Medical (NASDAQ:NXTM) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. NxStage Medical earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 45.812378637084 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

NxStage Medical (NXTM) traded up 0.40% on Tuesday, hitting $27.76. The stock had a trading volume of 705,273 shares. NxStage Medical has a 12 month low of $20.45 and a 12 month high of $30.80. The company has a 50-day moving average of $27.70 and a 200 day moving average of $25.86. The company’s market cap is $1.83 billion.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.03). The firm had revenue of $92.20 million for the quarter, compared to analyst estimates of $96.47 million. NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The business’s revenue was up .0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.03) earnings per share. On average, analysts predict that NxStage Medical will post ($0.05) EPS for the current fiscal year.

NXTM has been the subject of several recent analyst reports. BidaskClub upgraded NxStage Medical from a “hold” rating to a “buy” rating in a research note on Friday, June 30th. Craig Hallum initiated coverage on NxStage Medical in a research note on Tuesday, June 27th. They issued a “buy” rating and a $32.00 price target for the company. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research note on Thursday, August 10th. Stephens downgraded NxStage Medical from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $33.00 to $30.00 in a research note on Wednesday, August 9th. Finally, Canaccord Genuity downgraded NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price target for the company. in a research note on Monday, August 7th. Two analysts have rated the stock with a sell rating and eight have given a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $30.25.

TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/nxstage-medical-nxtm-getting-somewhat-positive-news-coverage-accern-reports/1637009.html.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 7,000 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $22.98, for a total transaction of $160,860.00. Following the transaction, the president now owns 82,903 shares of the company’s stock, valued at $1,905,110.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $29.21, for a total value of $102,235.00. Following the transaction, the senior vice president now directly owns 16,270 shares in the company, valued at approximately $475,246.70. The disclosure for this sale can be found here. Insiders sold 50,400 shares of company stock worth $1,406,020 over the last ninety days. Corporate insiders own 4.70% of the company’s stock.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.